MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Ocular Therapeutix Inc

Geschlossen

BrancheGesundheitswesen

9.64 3.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.59

Max

9.7

Schlüsselkennzahlen

By Trading Economics

Einkommen

-16M

-64M

Verkäufe

-6.4M

11M

EPS

-0.372

Gewinnspanne

-602.342

Angestellte

274

EBITDA

-20M

-64M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+82.95% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

154M

1.5B

Vorheriger Eröffnungskurs

5.76

Vorheriger Schlusskurs

9.64

Nachrichtenstimmung

By Acuity

50%

50%

146 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Ocular Therapeutix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juli 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. Juli 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Juli 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4. Juli 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4. Juli 2025, 15:49 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4. Juli 2025, 15:49 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4. Juli 2025, 15:49 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Received All Required Authorizations

4. Juli 2025, 15:48 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4. Juli 2025, 15:47 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: Agreement Was Announced on Dec. 19

4. Juli 2025, 15:47 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4. Juli 2025, 15:46 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4. Juli 2025, 14:30 UTC

Akquisitionen, Fusionen, Übernahmen

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4. Juli 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4. Juli 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4. Juli 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4. Juli 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Juli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4. Juli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4. Juli 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4. Juli 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4. Juli 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4. Juli 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Ocular Therapeutix Inc Prognose

Kursziel

By TipRanks

82.95% Vorteil

12-Monats-Prognose

Durchschnitt 17.6 USD  82.95%

Hoch 22 USD

Tief 14 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocular Therapeutix Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

11

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

6.97 / 7.62Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

146 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.